Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types

Narayan Shivapurkar, Shinichi Toyooka, Kiyomi O. Toyooka, Kiyomi O. Toyooka, Jyotsna Reddy, Kuniharu Miyajima, Makoto Suzuki, Hisayuki Shigematsu, Takao Takahashi, Gunjan Parikh, Harvey I. Pass, Preet M. Chaudhary, Adi F. Gazdar

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) selectively induces programmed cell death (apoptosis) in various cancer cells but not in normal cells. TRAIL is known to bind to 4 different receptors, 2 proapoptotic (DR4 and DR5), and 2 potentially antiapoptotic receptors lacking death domains (DcR1 and DcR2). Aberrant promoter methylation and resultant silencing of tumor suppressor genes play an important role in the pathogenesis of many tumor types. Recently aberrant methylation of TRAIL decoy receptors was reported in pediatric tumor cell lines and neuroblastomas. We examined the methylation and expression status of TRAIL receptor genes in cancers of breast, lung, mesothelioma, prostate, bladder, cervix, ovary, brain and in hematopoietic malignancies. Aberrant methylation of DcR1 or DcR2 was present in 70% of primary breast cancers, 31% of primary lung cancers, in 63% of primary malignant mesothelioma (MM), in 60% of prostate cancer, in 42% of bladder cancer, in 100% of cervical cancer, in 43% of ovarian cancer, in 41% of lymphoma, in 26% of leukemia and in 56% of multiple myeloma. Methylation of DR4 and DR5 was rare in all the tumor types examined. Methylation of all the 4 receptors was rare in non malignant tissues. In cell lines, aberrant methylation of DcR1 was present in 11 of 23 (48%) breast, 10 of 27 (37%) lung and 3 of 7 (43%) MM, whereas aberrant methylation of DcR2 was present in 17 of 23 (74%) breast, 13 of 27 (48%) lung and 5 of 7 (71%) MM. The concordance between loss of gene expression and aberrant methylation ranged from 70-100%. Treatment with 5-aza-2′-deoxycytidine restored DcR1 and DcR2 expression in 9 methylated cell lines confirming that aberrant methylation was the cause for silencing of DcR1 and DcR2 expression. Our results demonstrate that DcR1 and DcR2 genes are frequently methylated in various tumor types, and that the role of decoy receptors in tumor pathogenesis needs to be re-evaluated.

Original languageEnglish
Pages (from-to)786-792
Number of pages7
JournalInternational Journal of Cancer
Volume109
Issue number5
DOIs
Publication statusPublished - May 1 2004
Externally publishedYes

Fingerprint

Methylation
Genes
Neoplasms
TNF-Related Apoptosis-Inducing Ligand
TNF-Related Apoptosis-Inducing Ligand Receptors
decitabine
Lung Neoplasms
Breast
Breast Neoplasms
Cell Line
Lung
Death Domain Receptors
Mesothelioma
Hematologic Neoplasms
Tumor Cell Line
Tumor Suppressor Genes
Multiple Myeloma
Neuroblastoma
Urinary Bladder Neoplasms
Cervix Uteri

Keywords

  • Apoptosis
  • Breast cancer
  • Decoy receptors
  • Lung cancer
  • Malignant mesothelioma
  • Methylation
  • TRAIL

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shivapurkar, N., Toyooka, S., Toyooka, K. O., Toyooka, K. O., Reddy, J., Miyajima, K., ... Gazdar, A. F. (2004). Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. International Journal of Cancer, 109(5), 786-792. https://doi.org/10.1002/ijc.20041

Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. / Shivapurkar, Narayan; Toyooka, Shinichi; Toyooka, Kiyomi O.; Toyooka, Kiyomi O.; Reddy, Jyotsna; Miyajima, Kuniharu; Suzuki, Makoto; Shigematsu, Hisayuki; Takahashi, Takao; Parikh, Gunjan; Pass, Harvey I.; Chaudhary, Preet M.; Gazdar, Adi F.

In: International Journal of Cancer, Vol. 109, No. 5, 01.05.2004, p. 786-792.

Research output: Contribution to journalArticle

Shivapurkar, N, Toyooka, S, Toyooka, KO, Toyooka, KO, Reddy, J, Miyajima, K, Suzuki, M, Shigematsu, H, Takahashi, T, Parikh, G, Pass, HI, Chaudhary, PM & Gazdar, AF 2004, 'Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types', International Journal of Cancer, vol. 109, no. 5, pp. 786-792. https://doi.org/10.1002/ijc.20041
Shivapurkar, Narayan ; Toyooka, Shinichi ; Toyooka, Kiyomi O. ; Toyooka, Kiyomi O. ; Reddy, Jyotsna ; Miyajima, Kuniharu ; Suzuki, Makoto ; Shigematsu, Hisayuki ; Takahashi, Takao ; Parikh, Gunjan ; Pass, Harvey I. ; Chaudhary, Preet M. ; Gazdar, Adi F. / Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. In: International Journal of Cancer. 2004 ; Vol. 109, No. 5. pp. 786-792.
@article{2236c6258fd14000bd8fedfd86a40e75,
title = "Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types",
abstract = "TNF-related apoptosis-inducing ligand (TRAIL) selectively induces programmed cell death (apoptosis) in various cancer cells but not in normal cells. TRAIL is known to bind to 4 different receptors, 2 proapoptotic (DR4 and DR5), and 2 potentially antiapoptotic receptors lacking death domains (DcR1 and DcR2). Aberrant promoter methylation and resultant silencing of tumor suppressor genes play an important role in the pathogenesis of many tumor types. Recently aberrant methylation of TRAIL decoy receptors was reported in pediatric tumor cell lines and neuroblastomas. We examined the methylation and expression status of TRAIL receptor genes in cancers of breast, lung, mesothelioma, prostate, bladder, cervix, ovary, brain and in hematopoietic malignancies. Aberrant methylation of DcR1 or DcR2 was present in 70{\%} of primary breast cancers, 31{\%} of primary lung cancers, in 63{\%} of primary malignant mesothelioma (MM), in 60{\%} of prostate cancer, in 42{\%} of bladder cancer, in 100{\%} of cervical cancer, in 43{\%} of ovarian cancer, in 41{\%} of lymphoma, in 26{\%} of leukemia and in 56{\%} of multiple myeloma. Methylation of DR4 and DR5 was rare in all the tumor types examined. Methylation of all the 4 receptors was rare in non malignant tissues. In cell lines, aberrant methylation of DcR1 was present in 11 of 23 (48{\%}) breast, 10 of 27 (37{\%}) lung and 3 of 7 (43{\%}) MM, whereas aberrant methylation of DcR2 was present in 17 of 23 (74{\%}) breast, 13 of 27 (48{\%}) lung and 5 of 7 (71{\%}) MM. The concordance between loss of gene expression and aberrant methylation ranged from 70-100{\%}. Treatment with 5-aza-2′-deoxycytidine restored DcR1 and DcR2 expression in 9 methylated cell lines confirming that aberrant methylation was the cause for silencing of DcR1 and DcR2 expression. Our results demonstrate that DcR1 and DcR2 genes are frequently methylated in various tumor types, and that the role of decoy receptors in tumor pathogenesis needs to be re-evaluated.",
keywords = "Apoptosis, Breast cancer, Decoy receptors, Lung cancer, Malignant mesothelioma, Methylation, TRAIL",
author = "Narayan Shivapurkar and Shinichi Toyooka and Toyooka, {Kiyomi O.} and Toyooka, {Kiyomi O.} and Jyotsna Reddy and Kuniharu Miyajima and Makoto Suzuki and Hisayuki Shigematsu and Takao Takahashi and Gunjan Parikh and Pass, {Harvey I.} and Chaudhary, {Preet M.} and Gazdar, {Adi F.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1002/ijc.20041",
language = "English",
volume = "109",
pages = "786--792",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types

AU - Shivapurkar, Narayan

AU - Toyooka, Shinichi

AU - Toyooka, Kiyomi O.

AU - Toyooka, Kiyomi O.

AU - Reddy, Jyotsna

AU - Miyajima, Kuniharu

AU - Suzuki, Makoto

AU - Shigematsu, Hisayuki

AU - Takahashi, Takao

AU - Parikh, Gunjan

AU - Pass, Harvey I.

AU - Chaudhary, Preet M.

AU - Gazdar, Adi F.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - TNF-related apoptosis-inducing ligand (TRAIL) selectively induces programmed cell death (apoptosis) in various cancer cells but not in normal cells. TRAIL is known to bind to 4 different receptors, 2 proapoptotic (DR4 and DR5), and 2 potentially antiapoptotic receptors lacking death domains (DcR1 and DcR2). Aberrant promoter methylation and resultant silencing of tumor suppressor genes play an important role in the pathogenesis of many tumor types. Recently aberrant methylation of TRAIL decoy receptors was reported in pediatric tumor cell lines and neuroblastomas. We examined the methylation and expression status of TRAIL receptor genes in cancers of breast, lung, mesothelioma, prostate, bladder, cervix, ovary, brain and in hematopoietic malignancies. Aberrant methylation of DcR1 or DcR2 was present in 70% of primary breast cancers, 31% of primary lung cancers, in 63% of primary malignant mesothelioma (MM), in 60% of prostate cancer, in 42% of bladder cancer, in 100% of cervical cancer, in 43% of ovarian cancer, in 41% of lymphoma, in 26% of leukemia and in 56% of multiple myeloma. Methylation of DR4 and DR5 was rare in all the tumor types examined. Methylation of all the 4 receptors was rare in non malignant tissues. In cell lines, aberrant methylation of DcR1 was present in 11 of 23 (48%) breast, 10 of 27 (37%) lung and 3 of 7 (43%) MM, whereas aberrant methylation of DcR2 was present in 17 of 23 (74%) breast, 13 of 27 (48%) lung and 5 of 7 (71%) MM. The concordance between loss of gene expression and aberrant methylation ranged from 70-100%. Treatment with 5-aza-2′-deoxycytidine restored DcR1 and DcR2 expression in 9 methylated cell lines confirming that aberrant methylation was the cause for silencing of DcR1 and DcR2 expression. Our results demonstrate that DcR1 and DcR2 genes are frequently methylated in various tumor types, and that the role of decoy receptors in tumor pathogenesis needs to be re-evaluated.

AB - TNF-related apoptosis-inducing ligand (TRAIL) selectively induces programmed cell death (apoptosis) in various cancer cells but not in normal cells. TRAIL is known to bind to 4 different receptors, 2 proapoptotic (DR4 and DR5), and 2 potentially antiapoptotic receptors lacking death domains (DcR1 and DcR2). Aberrant promoter methylation and resultant silencing of tumor suppressor genes play an important role in the pathogenesis of many tumor types. Recently aberrant methylation of TRAIL decoy receptors was reported in pediatric tumor cell lines and neuroblastomas. We examined the methylation and expression status of TRAIL receptor genes in cancers of breast, lung, mesothelioma, prostate, bladder, cervix, ovary, brain and in hematopoietic malignancies. Aberrant methylation of DcR1 or DcR2 was present in 70% of primary breast cancers, 31% of primary lung cancers, in 63% of primary malignant mesothelioma (MM), in 60% of prostate cancer, in 42% of bladder cancer, in 100% of cervical cancer, in 43% of ovarian cancer, in 41% of lymphoma, in 26% of leukemia and in 56% of multiple myeloma. Methylation of DR4 and DR5 was rare in all the tumor types examined. Methylation of all the 4 receptors was rare in non malignant tissues. In cell lines, aberrant methylation of DcR1 was present in 11 of 23 (48%) breast, 10 of 27 (37%) lung and 3 of 7 (43%) MM, whereas aberrant methylation of DcR2 was present in 17 of 23 (74%) breast, 13 of 27 (48%) lung and 5 of 7 (71%) MM. The concordance between loss of gene expression and aberrant methylation ranged from 70-100%. Treatment with 5-aza-2′-deoxycytidine restored DcR1 and DcR2 expression in 9 methylated cell lines confirming that aberrant methylation was the cause for silencing of DcR1 and DcR2 expression. Our results demonstrate that DcR1 and DcR2 genes are frequently methylated in various tumor types, and that the role of decoy receptors in tumor pathogenesis needs to be re-evaluated.

KW - Apoptosis

KW - Breast cancer

KW - Decoy receptors

KW - Lung cancer

KW - Malignant mesothelioma

KW - Methylation

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=12144286953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144286953&partnerID=8YFLogxK

U2 - 10.1002/ijc.20041

DO - 10.1002/ijc.20041

M3 - Article

VL - 109

SP - 786

EP - 792

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -